Last reviewed · How we verify
NCT07290972: NCG-Compliance
Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India
trial testing Not applicable- observational study in Cervical Cancer Screening in 618 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Tata Memorial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 618 |
| Start date | 1 February 2021 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 March 2026 |
| Sites | 2 locations across India |
Drugs / interventions tested
- Not applicable- observational study — full drug profile →
Conditions studied
- Cervical Cancer Screening — all drugs for Cervical Cancer Screening →
- Gynecologic Cancers — all drugs for Gynecologic Cancers →
- Treatment Compliance — all drugs for Treatment Compliance →
- Chemoradiotherapy — all drugs for Chemoradiotherapy →
Sponsor
Tata Memorial Hospital
Who can join
Eligibility, female only, with Cervical Cancer Screening or Gynecologic Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+/- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and/or concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included. As a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing. Each of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted. Those centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and /or concurrent chemotherapy over a period of 6 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07290972
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Not applicable- observational study
Trials testing the same drug.
- NCT07518433 — Study on Serum Transcriptomics and Metabolomics in Patients With Diabetic Peripheral Neuropathy · not yet recruiting
- NCT07416760 — Analysis of the Composition of the Intestinal Microbiota in Patients Post-intestinal Anastomosis · recruiting
- NCT07422584 — Cytokine Response to Abdominal Wall Reconstruction · recruiting
- NCT07260617 — Association Between Composition of the Gut Microbiota and Nutritional Status in Digestive Oncology · not yet recruiting
- NCT07178626 — Association of Biomarkers and Gastric Antral Motility Index With Feeding Intolerance in Critically Ill Patients · enrolling by invitation
Other recruiting trials for Cervical Cancer Screening
Currently open trials in the same condition.
- NCT06968871 — Ameliorated Pap Tests and Cervical Cancer Screening Participation · NA · recruiting
- NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
- NCT07171658 — Breast Cancer-Related Approach for Increasing Cervical Cancer Screening · NA · recruiting
- NCT07581873 — Education and Health in Women With Cervical Cancer · NA · active not recruiting
- NCT07181278 — Optimization of Cervical Cancer Screening Strategies Among Women Living With HIV: Effectiveness and Implementation of De · NA · recruiting
Other Tata Memorial Hospital trials
Trials by the same sponsor.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT07196033 — Asian Gynecological Brachytherapy Registry in Cervical Cancer · recruiting
- NCT06804135 — Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer · recruiting
- NCT07435623 — Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study · recruiting
- NCT07342231 — FAPi PET in Pancreatic Ductal Adenocarcinoma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07290972 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tata Memorial Hospital
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07290972.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing